Rockefeller Capital Management
ACHL

Rockefeller Capital Management’s Achilles Therapeutics ACHL Stock Holding History

Rockefeller Capital Management’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-250
Closed – – 4279
2022
Q3 		$0 Hold
250
– – ﹤0.01% 4467
2022
Q2 		$0 Hold
250
– – ﹤0.01% 4448
2022
Q1 		$0 Hold
250
– – ﹤0.01% 4104
2021
Q4 		$1K Hold
250
– – ﹤0.01% 3709
2021
Q3 		$1K Hold
250
– – ﹤0.01% 3634
2021
Q2 		$2K Buy
+250
New +$3.39K ﹤0.01% 3283

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Rockefeller Capital Management's ACHL Position: Q4 2022 in Review

Rockefeller Capital Management sold out of Achilles Therapeutics (ACHL) in Q4 2022, closing a stake of 250 shares.

Rockefeller Capital Management first reported a position in ACHL in Q2 2021 and held it in 6 quarters. The position peaked at $2K in Q2 2021. 23 funds tracked by Wall St. Rank hold ACHL as of Q4 2022.

  • Rockefeller Capital Management reported no remaining Achilles Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Rockefeller Capital Management sold 250 Achilles Therapeutics shares in Q4 2022.
  • Rockefeller Capital Management first reported a position in Achilles Therapeutics in Q2 2021 and held it in 6 quarters.
  • Rockefeller Capital Management's Achilles Therapeutics position peaked at $2K in Q2 2021.
  • 23 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q4 2022.

Based on Rockefeller Capital Management's 13F filing for Q4 2022, filed 6 Mar 2023.